129P Tislelizumab combined with bevacizumab plus nab-paclitaxel single-agent chemotherapy for advanced NSCLC after resistance to EGFR TKIs. (December 2022) - Zhou, C.; Xie, X.; Yang, Y.; Lin, X.; Xie, Z.; Zhou, M.; Qin, Y.; Zhang, J.